Zusammenfassung
In der Bundesrepublik Deutschland gelten derzeit ca. 2,5–4 Mio. Menschen als alkohol-, ca. 120 000 Menschen als drogen- und etwa 1,5 Mio. als medikamentenabhängig. Ein Großteil der Abhängigen gerät suchtbedingt in Konflikt mit dem Gesetz; über die juristische Aufarbeitung der Rechtsverstöße ist das Fach Rechtsmedizin in vielfältiger Weise mit den Problemen Süchtiger konfrontiert. Nur am Rande seien typische rechtsmedizinische Aufgaben erwähnt: Nachweis von Alkohol, Drogen und Medikamenten in verschiedenen biologischen Matrizes, z. B. zur Beurteilung der Fahrtüchtigkeit oder zur Beurteilung der tatzeitrelevanten psychophysischen Beeinträchtigung und Schuldfähigkeit oder zur Kontrolle der Abstinenz im Rahmen der Resozialisation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Allievi C, Dostert P, Strolin Benedetti M (1991) Determination of free salsolinol concentrations in human urine using gas chromatography-mass spectrometry. J Chromatogr 568: 271–279
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 80: 4546–4550
Chiba K, Trevor AJ, Castagnoli N (1984) Metabolism of the neurotoxic amine, MPTP, by brain mono amine oxidase. Biochem. Biophys Res Commun 120: 574–578
Clow A, Topham A, Saunders JB, Murray R, Sandler M (1985) The role of salsolinol in alcoholic intake and withdrawal. Prog Clin Biol Res 183: 101–113
Cohen G, Collins M (1970) Alkaloids from catecholamines in adrenal tissue: possible role in alcoholism. Science 167: 1749–1751
Collins MA (1982) A possible neurochemical mechanism for brain and nerve damage associated with chronic alcoholism. Trends Pharmacol Sci 3: 373–375
Collins MA (1988) Acetaldehyde and its condensation products as markers in alcoholism. Recent Dev Alcohol 6: 387–403
Collins MA, Nijm WP, Borge G, Teas G, Goldfarb C (1979) Dopamine-related tetrahydroisoquinolines. Significant urinary excretion by alcoholics following alcohol consumption. Science 206: 1184–1186
Davis VE, Walsh MJ (1970) Alcohol, amines, and alkaloids: a possible biochemical basis for alcohol addiction. Science 167: 1005–1007
Deng Y, Maruyama W, Dostert P, Takahashi T, Kawai M, Naoi M (1995) Determination of the (R)-and (S)enantiomers of salsolinol and N-methylsalsolinol by use of a chiral high-performance liquid chromatographic column. J Chromatogr B 670: 47–54
Dostert P, Strolin Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson’s and Huntington’s disease. J Neural Transm 74: 61–74
Dostert P, Strolin Benedetti M, Dordain G, Vernay D (1991) Urinary elimination of salsolinol enantiomers in alcoholics. J Neural Transm 85: 51–59
Dufay C, Lecron JC, Daudon F, Gombert J (1991) Rapid and simple procedure for the determination of salsolinol in urine using high-performance liquid chromatography with electrochemical detection [letter]. J Chromatogr 563: 224–227
Faraj BA, Camp VM, Davis DC, Lenton JD, Kutner M (1989) Elevation of plasma salsolinol suffate in chronic alcoholics as compared to nonalcoholics. Alcohol Clin Exp Res 13: 155–163
Feest U, Kemper A, Nickel B, Rabe H, Koalick F (1991) Comparison of salsolinol excretion in alcoholics and nonalcoholic controls. Alcohol 9: 49–52
Feuerlein W, Küfner H, Soyka M (1998) Alkoholismus-Mißbrauch und Abhängigkeit, 5. Aufl. Thieme, Stuttgart
Genazzani AR, Nappi G, Facchinetti F et al. (1982) Central deficiency of β-endorphin in alcohol addicts. Clin Endocrinol Metab 55: 583–586
Haber H, Henklein P, Georgi M, Melzig MF (1995) Resolution of catecholic tetrahydroisoquinoline enantiomers and the determination of R-and S-salsolinol in biological samples by gas chromatography-mass spectrometry. J Chromatogr B 672: 179–187
Haber H, Melzig M (1992) Tetrahydroisochinoline — endogene Produkte nach chronischem Alkoholmissbrauch. Pharmazie 47: 3–7
Haber H, Putscher I, Georgi M, Melzig MF (1995) Influence of ethanol on the salsolinol excretion in healthy subjects. Alcohol 12: 299–303
Haber H, Winkler A, Putscher I et al. (1996) Plasma and urine salsolinol in humans: Effect of acute ethanol intake on the enantiomeric composition of salsolinol. Alcoholism Clin Exp Res 20: 87–92
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Maruyama W, Abr T, Toghi H, Dostert P, Naoi M (1996) A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian CSF. Ann Neurol 40: 119–122
Maruyama W, Dostert P, Matsubara K, Naoi M (1995) N-methyl(R)salsolinol pro duces hydroxyl radicals: involvement to neurotoxicity. Free Radic Biol Med 19: 67–75
Maruyama W, Narabayashi H, Dostert P, Naoi M (1996) Stereospecific occurrence of a parkinsonism-inducing catechol isoquinoline, N-methyl(R)salsolinol, in the human intraventricular fluid. J Neural Transm 103: 1069–1076
Maruyama W, Sobue G, Matsubara K et al. (1997) A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2, 3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigrostriatal system of the human brain. Neurosci Lett 223: 61–64
Melchior C (1979) Behavioral and biochemical effects of intracerebrally injected alkaloids. Drug Alcohol Depend 4: 347
Melzig MF, Putscher I, Haber H, Rottmann M, Zipper J (1998) Toxicity and pharmacological effects of salsolinol in different cultivated cells. In: Moser A (ed) Pharmacology of endogenous neurotoxins — A handbook. Birkhäuser, Boston
Moser A (1998) Pharmacology of endogenous neurotoxins — A handbook. Birkhäuser, Boston
Müller T, Przuntek H, Kuhn W et al. (1999) No increase of synthesis of (R)salsolinol in Parkinson’s disease. Mov Disord 14: 514–515
Müller T, Sällström Baum S, Haussermann P et al. (1998) Plasma levels of R-and S-salsolinol are not increased in “de-novo” Parkinsonian patients. J Neural Transm 105: 239–246
Mußhoff F (1995) Formaldehyd-Neuroamin-Kondensationsprodukte bei chronischen Alkoholikern. Dr. Köster, Berlin
Mußhoff F, Daldrup T (1998) Determination of biological markers for alcohol abuse (Review). J Chromatogr B 713: 245–264
Mußhoff F, Daldrup T, Bonte W, Leitner A, Lesch OM (1996) Formaldehyde-derived tetrahydroisoquinolines and tetrahydro-β-carbolines in human urine. J Chromatogr 683: 163–176
Mußhoff F, Daldrup T, Bonte W, Leitner A, Lesch OM (1997) Salsolinol and norsalsolinol in human urine samples. Pharmacol Biochem Behav 58: 545–550
Mußhoff F, Schmidt P, Dettmeyer R, Priemer F, Jachau Kadea B (2000) Determination of dopamine and dopamine-derived (R)-/(S)-salsolinol and norsalsolinol in various human brain areas using solid-phase extraction (SPE) and gas chromatography/mass spectrometry (GC/MS). Forensic Sci Int 113: 359–366
Mußhoff F, Schmidt P, Dettmeyer R, Priemer F, Wittig H, Madea B (1999) A systematic regional study of dopamine and dopamine-derived salsolinol and norsalsolinol levels in human brain areas. Forensic Sci Int 105: 1–11
Myers RD (1989) Isoquinolines, beta-carbolines and alcohol drinking: involvemnt of opioid and dopaminergic mechanisms. Experientia 45: 436–443
Myers RD, Melchior CL (1977) Alcohol drinking: Abnormal intake cause by tetrahydropapaveroline in brain. Science 196: 554–556
Myers RD, Melchior CL (1977) Differential actions on voluntary alcohol intake of tetrahydroisoquinolines or a beta-carboline infused chronically in the ventricle of the rat. Pharmacol. Biochem Behav 7: 381–392
Myers RD, Privette H (1989) A neuroanatomical substrate for alcohol drinking: identification of tetrahydropapaveroline (THP)-reactive sites in the rat brain. Brain Res Bull 22: 899–911
Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson’s disease. Neurosci Res 29: 99–111
Naoi M, Maruyama W (1999) N-methyl(R )salsolinol, a dopamine neurotoxin, in Parkinson’s disease. Adv Neurol 80: 259–264
Naoi M, Maruyama W, Dostert P (1995) Dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines; oxidation and neurotoxicity. Prog Brain Res 106: 227–239
Naoi M, Maruyama W, Dostert P, Kohda K, Kaiya T (1996) A novel enzyme enantio-selectively synthesizes (R)salsolinol, aprecursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol. Neurosci Lett 212: 183–186
Naoi M, Maruyama W, Matsubara K, Hashizume Y (1997) A neutral N-methyltransferase activity in the striatum determines the level of an endogenous MPP+-like neurotoxin, 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion, in the substantia nigra of human brains. Neurosci Lett 235: 81–84
Naoi M, Maruyama W, Zhang JH et al. (1995) Enzymatic oxidation of the dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1, 2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion. Life Sci 57: 1061–1066
Privette H, Myers RD (1989) Anatomical mapping of tetrahydropapaveroline-reactive sites in brain mediating suppression of alcohol drinking in the rat. Brain Res Bull 22: 1039–1048
Rimpler H (1990) Biogene Arzneistoffe — Pharmazeutische Biologie II. Thieme, Stuttgart
Rommelspacher H (1999) Modelle der Entstehung und Aufrechterhaltung süchtigen Verhaltens. In: Gastpar M, Mann K, Rommelspacher H (Hrsg) Lehrbuch der Suchterkrankungen. Thieme, Stuttgart, S 28–38
Rommelspacher H, Sällström Baum S, Dufeu P, Schmidt LG (1995) Determination of (R)-and (S)-salsolinol sulfate and dopamine sulfate levels in plasma of nonalcoholics and alcoholics. Alcohol 12: 309–315
Rommelspacher H, Susilo R (1985) Tetrahydroisoquinolines and β-carbolines: putative natural substances in plants and mammals. Prog Drug Res 29: 415–459
Sällström Baum S, Rommelspacher H (1994) Determination of total dopamine, R-and S-salsolinol in human plasma by cyclodextrin bonded-phase liquid chromatography with electrochemical detection. J Chromatogr B 660: 235–241
Sjöquist B, Borg S, Kavande H (1981) Catecholamine derived compounds in urine and cerebrospinal fluid from alcoholics during and after long-standing intoxication. Subst Alcohol Action Misuse 2: 63–72
Strolin Benedetti M, Bellotti U, Pianezzola E et al. (1989) Ratio of the Rand S enantiomer of salsolinol in food and human urine. J Neural Transm 77: 47–53
Arvidsson U, Riedl M, Chakrabarti S et al. (1995) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15: 3328–3341.
Bankfalvi A, Schmid KE (1994) In-situ-Hybridisierung. Theoretische Grundlagen und praktische Anwendung. Pathologe 15: 76–84
Bockstaeie EJ v, Colago EEO, Cheng P, Moriwaki A, Uhl GR, Pickel VM (1996) Ultrastructural evidence for prominent distribution of the mu-opioid receptor at extrasynaptic sites on noradrenergic dendrites in the rat nucleus locus coeruleus. J Neurosci 16: 5037–5048
Bonnet U, Gastpar M (1999) Opioide. In: Gastpar M, Mann K, Rommelspacher H (Hrsg) Lehrbuch der Suchterkrankungen, Einleitung und Geschichte. Thieme, Stuttgart, S 237–262
Brady LS, Herkenham M, Long JB, Rothman RB (1989) Chronic morphine increases mu-opiate receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 477: 382–386
Brodsky M, Elliott K, Hynansky A, Inturrisi CE (1995) CNS Levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res Bull 38: 135–141
Busquets X, Escriba PV, astre M, Garcia-Sevilla JA (1995) Loss of protein kinase C-alpha beta in brain of heroin addicts and morphine-dependent rats. J Neurochem 64: 247–252
Buzas B, Rosenberger J, Cox BM (1996) Mu-and deltaopioid receptor gene expression after chronic treatment with opioid agonist. Neuroreport 7: 1505–1508
Castelli MP, Melis M, Mameli M et al. (1997) Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. Mol Brain Res 45: 149–153
Childers SR (1991) Opioid receptor-coupled second messenger systems. Life Sci 48: 1991–2003
Connor M, McDonald JC (1999) Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 26: 493–499
Danks JA, Tortella FC, Long JB et al. (1988) Chronic administration of morphine and naltrexone up-regulate [3H] (D-ALA2,D-LEU5) enkephalin binding sites by different mechanisms. Neuropharmacology 27: 965–974
Ding Y-Q, Kaneko T, Nomura S, Mizuno N (1996) Immunohistochemical localization of mu-opioid receptors in the central nervous system of the rat. J Comp Neurol 367: 375–402
Escriba PV, Sastre M, Garcia-Sevilla JA (1994) Increased density of guanine nudeotide-binding proteins in the postmortem brains of heroin addicts. Arch Gen Psychiatry 51: 494–501
Garcia-Sevilla JA, Ventayol P, Busquets X, La Harpe R, Walzer C, Guimón J (1997) Regulation of immunolabelled mu-opioid receptors and protein kinase C-α and isoforms in the frontal cortex of human opiate addicts. Neurosci Lett 226: 29–32
Geschwinde T (1996) Opium und Opiate. In: Geschwinde T (Hrsg) Rauschdrogen, Marktformen und Wirkungsweisen, 3.Aufl. Springer, Berlin Heidelberg New York Tokio, S 197–288
Harrison LM, Kastin AJ, Zadina JE (1998) Opiate tolerance and dependence: receptors, G-proteins and antiopiates. Peptides 19: 1603–1630
Herz A (1995) Neurobiologische Grundlagen des Suchtgeschehens. Nervenarzt 66: 3–14
Herz A (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology 129: 95–111
Hiller JH, Fan L-Q (1996) Laminar distribution of the multiple opioid receptors in the human cerebral cortex. Neurochem Res 21: 1333–1345
Holaday JW, Hitzemann RJ, Curell J et al. (1982) Repeated electroconvulsive shock or chronic morphine treatment increases the number of 3H-D-ALA2-D-LEU5-enkephalin binding sites in rat brain membranes. Life Sci 31: 2359–2362
Iten PX (1994) Datenblätter Opiate. In: Iten PX (Hrsg) Fahren unter Drogen-oder Medikamenteneinfluss. Institut für Rechtsmedizin der Universität Zürich, S 186–207
Jansen KLR, Faull RLM, Dragunow M, Leslie RA (1991) Distribution of exeitatory and inhibitory amino acid sigma, mono amine, catecholamine, acetylcholine, opioid, neurotensin, substance P, adenosine and neuropeptide Y receptors in human motor and somatosensory cortex. Brain Res 566: 225–238
Knapp RJ, Malatynska E, Collins N et al. (1995) Molecular biology and pharmacology of doned opioid receptors. FASEB L: 516–525
Koob GF (1992) Drugs of abuse “anatomy” pharmacology and function of reward pathways. TIPS 13: 177–184
Linder ME, Gilman AG (1992) G-Proteine. Spektrum-Wiss 92: 54–61
Magnan J, Paterson SJ, Tavami A, Osterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. NaunynSchmiedeberg’s Arch Pharmacol 319: 197–205
Mansour A, Fox CA, Thompson RC, Akil H, Watson SJ (1994) Mu-opioid receptor mRNA expression in the rat CNS: comparison to mu-receptor binding. Brain Res 643: 245–265
Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid receptor mRNA expression in the rat CNS: anatomical and functional implications. TINS 18: 22–29
Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. TINS 11: 308–315
Mayer P, Rochlitz H, Rauch E et al. (1997) Association between a delta-opioid receptor gene polymorphism and heroin dependence in man. Neuro Report 8: 2547–2550
Morris BJ, Herz A (1989) Control of opiate receptor number in vivo: simultaneous kappa-receptor downregulation and mu-receptor up-regulation following chronic agonist/antagonist treatment. Neuroscience 29: 433–442
Mutschier E (1996) Opioid-Analgetika. In: Mutschier E (Hrsg) Arzneimittelwirkungen, 7. Aufl. Wiss. Verlagsges., Stuttgart, S 188–194
Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 278: 58–62
O’Brien CP, Terenius LY, Nyberg F, McLellan AT, Eriksson I (1988) Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biol Psychiatry 24: 649–662
Peckys D, Landwehrmeyer GB (1999) Expression of mu, kappa and delta opiod receptor messenger RNA in the human CNS. A33]p in situ hybridization study. Neuroscience 88: 1093–1135
Pert CB, Snyder SH (1976) Opiate receptor binding-enhancement by opiate administration in vivo. Biochem Pharmacol 25: 847–853
Petruzzi R, Ferraro TN, Kürschner VC, Golden GT, Berrettini WH (1997) The effects of repeated morphine exposure on mu-opioid receptor number and affinity in C57BL/GJ and DBA/2 J mice. Life Sci 61: 2057–2064
Przewlocki R (1993) Opioid systems and stress. In: Herz A (Hrsg) Opioids. Springer, Berlin Heidelberg New York Tokio, S 293–324
Quirion R, Pilapil C, Allaoua H, Chaudieu I (1995) Autoradiographic distribution of multiple opioid, sigma, and phencydidine receptor binding sites in the human brain. In: Biegon A, Volkow ND (eds) Sites of drug action in the human brain. CRC Press, Boca Raton Ann Arbor London Tokyo, pp 117–141
Quock RM, Burkey TH, Varga E et al. (1999) The delta, opioid receptor: molecular pharmacology, signal transduction and the determination of drug efficacy. Pharmacol Rev 51: 503–527
Reisine T (1995) Opiate receptors. Neuropharmacol 34: 463–472
Reisine T, Pasternak G (1995) Opiod analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff MD, Raymond WR (eds) The pharmacological basis of therapeutics (Goodman & Gilman’s Edn). McGraw-Hill, New York, pp 521–555
Rommelspacher H (1999) Modelle der Entstehung und Aufrechterhaltung süchtigen Verhaltens. In: Gastpar M, Mann K, Rommelspacher H (Hrsg) Neurobiologische Ansätze, Lehrbuch der Suchterkrankungen. Thieme, Stuttgart, S 28–39
Rothman RB, Bykov V, Long JB et al. (1989) Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H] [D-Ala2, MePhe4, Gly-ol5]enkephalin: further evidence for two mu-binding sites. Eur J Pharmacol 160: 71–82
Rothmann RB, Danks JA, Jacobson AE et al. (1986) Morphine tolerance increases mu-noncompetitive delta binding sites. Eur J Pharmacol 124: 113–119
Sanchez-Blázquez P, Garcia-Espana A, Garzón J (1997) Antisense oligodeoxynudeotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2-opioid receptors. J Pharmacol Exp Ther 280: 1423–1431
Schmidt P, Schmolke C, Mußhoff F, Prohaska C, Menzen M, Madea B (2001) Numerical density of mu opioidreceptor expressing neurons in the frontal cortex of drug related fatalities. Forensic Sci Int 115: 219–229
Schröder H, Giacobini E, Struble RG et al. (1991) Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer’s disease. Brain Res Bull 27: 631–636
Schwartz JH, andel ER (1996) Modulation der synaptischen übertragung: Second-messenger-Systeme. In: Kandel ER, Schwartz JH, Jessell TM (Hrsg) Neurowissenschaften. Spektrum Akademischer Verlag, Heidelberg Berlin Oxford, S 249–273
Sharma SK, Klee WA, Nirenberg M (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72: 3092–3096
Simon EJ (1991) Opiate receptors and endogenous opioid peptides. Med Res Rev 11: 357–374
Standifer KM, Pasternak GW (1997) G-proteins and opioid receptor-mediated signalling. Cell Signal 9: 237–248
Sternberger LA (1986) Immunocytochemistry, 3rd edn. Wiley, New York, pp 1–524
Svingos AL, Moriwaki A, Wang JB, Uhl GR, Pickel VM (1996) Ultrastructural immunocytochemical localization of mu-opioid receptors in rat nucleus accumbens: Extrasynaptic plasmalemmal distribution and Association with Leu5-enkephalin. J Neurosci 16: 4162–4173
Tao P-L, Law P-Y, Loh HH (1987) Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment. J Pharmacol Exp Ther 240: 809–816
Turchan J, Przewlocka B, Toth G, Lason W, Borsodi A, Przewlocki R (1999) The effect of repeated administration of morphine, cocaine and ethanol on mu-and delta-opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience 91: 971–977
Unterwald EM, Rubenfeld JM, Imai Y et al. (1995) Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol Brain Res 33: 351–355
Ventayol P, Busquets X, Garcia-Sevilla JA (1997) Modulation of immunoreactive protein kinase C-alpha and beta isoforms and G proteins by acute and chronic treatments with morphine and other opiate drugs in rat brain. Naunyn-Schmiedeberg’s Arch Pharmacol 355: 491–500
Wamsley JK (1983) Opioid receptors: autoradiography. Pharmacol Rev 35: 69–83
Wang H, Moriwaki A, Wang JB, Uhl GR, Pickel VM (1997) Ultrastructural immunocytochemical localization of mu-opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate-putamen nucleus. Neuroscience 81: 757–771
Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR (1994) Human mu-opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 338: 217–222
Yoburn B C, Billings B, Duttaroy A (1993) Opioid receptor regulation in mice. J Pharmacol Exp Ther 265: 314–319
Zieglgänsberger W, Spanagel R (1999) Molekularbiologie der Sucht. In: Ganten D, Ruckpaul K (Hrsg) Erkrankungen des Zentralnervensystems, Handbuch der molekularen Medizin, Bd 5. Springer, Berlin Heidelberg New York Tokio, S 237–272
Zukin RS, Pellegrini-Giampietro DE, Knapp CM, Tempel A (1993) Opioid receptor regulation. In: Herz A (Hrsg) Opioids. Springer, Berlin Heidelberg New York Tokio, S 107–123
Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR (1982) Naltrexone-induced opiate receptor supersensitivity. Brain Res 245: 285–292
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Musshoff, E., Schmidt, P., Madea, B. (2003). Forensische Untersuchungen zur Suchtgenese. In: Madea, B., Brinkmann, B. (eds) Handbuch gerichtliche Medizin 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55866-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-55866-5_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63055-2
Online ISBN: 978-3-642-55866-5
eBook Packages: Springer Book Archive